Head to head
InnovAge Holding vs HCA Healthcare
Side-by-side on the measures that matter, with a plain-English read. Full detail: INNV · HCA
INNV
InnovAge Holding
9.13+1.44%
1-year price shape — +75% over the period
Quant Rating B · 90/100
vs
HCA
HCA Healthcare
439.17+1.61%
1-year price shape — +1% over the period
Quant Rating D · 41/100
1-year performance, rebased to 100
HCA Healthcare edges it on the scoreable measures. HCA Healthcare pays the highest dividend yield; HCA Healthcare earns the most per share.
| INNV | HCA | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 9.13 | 439.17 |
| Change today | +1.44% | +1.61% |
| 1-year return | +75.2% | +0.9% |
| Market cap | $1.25B | $95.08B |
| 52-week range | 3.94 – 12.64 | 353.34 – 553.56 |
| Valuation | ||
| P/E (TTM) | -456.50 | 14.73 |
| P/E percentile, own 5-yr range | 1st | 55th |
| P/B | 5.29 | -14.32 |
| Dividend yield | 0.00% | 0.68% |
| Profitability & growth | ||
| EPS (TTM) | -0.02 | 28.33 |
| Net profit (TTM) | $-2.73M | $6.13B |
| Revenue (TTM) | $989.71M | $78.01B |
| Revenue growth (YoY) | +18.3% | +8.7% |
| Gross margin | 23.0% | 42.6% |
| Operating margin | 0.6% | 15.5% |
| Net margin | -0.3% | 8.8% |
| Free cash flow (TTM) | $50.41M | $6.00B |
| Ownership & sentiment | ||
| Institutional ownership | 88.8% | 94.6% |
| Insider activity (12mo) | 30 buy / 19 sell | 22 buy / 23 sell |
| Short interest (% of float) | 0.9% | 3.0% |
| Analyst consensus | 33% buy / 33% hold / 33% sell (3) | 64% buy / 32% hold / 5% sell (22) |
| Analyst price target | $12 (+31%) | $457 (+4%) |
| StockVane view | ||
| StockVane Quant Rating | B (90) | D (41) |
| Company | ||
| Employees | 2,500 | 320,000 |
| Founded | 2007 | 1968 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.